Table 3.
Comparison of tumor characteristics between patients with hepatocellular carcinoma with resistant chronic hepatitis B (R group) and hepatocellular carcinoma with chronic hepatitis B treated with antivirals (N group) n (%)
| Variables | R group (n = 57) | N group (n = 119) | P-value |
| Gender (male) | 42 (73.7) | 100 (84) | 0.158 |
| Age (mean, yr) | 57.44 ± 8.35 | 55.37 ± 10.61 | 0.161 |
| Presence of cirrhosis | 55 (96.5) | 117 (98.3) | 1 |
| Portal vein thrombosis | 8 (14) | 43 (36.1) | 0.004 |
| Vascular invasion | 20 (35.1) | 47 (39.5) | 0.623 |
| Multi-nodular tumor type | 21 (36.8) | 55 (46.2) | 0.259 |
| CLIP score | 0.75 ± 0.85 | 1.67 ± 1.43 | < 0.001 |
| Modified UICC stage (< IVA) | 50 (87.7) | 73 (61.3) | < 0.001 |
| Modified UICC stage (I/II/III/IVA/IVB) | 13/18/19/6/1 | 18/34/21/28/18 | |
| LN involvement | 1 (2.1) | 14 (11.7) | 0.071 |
| Distant metastasis | 0 (0) | 13 (10.9) | 0.019 |
| AST U/L (median, range) | 48 (20-415) | 61 (16-481) | 0.022 |
| ALT U/L (median, range) | 39 (8-532) | 44 (3-203) | 0.616 |
| Platelet count (103/mm3), (median, range) | 103 (23-380) | 126 (24-426) | 0.009 |
| CRP (mg/dL) (median, range) | 0.34 ± 0.37 | 1.71 ± 2.75 | < 0.001 |
| AFP IU/mL (median, range) | 48 (2-40591) | 107 (2-50000) | 0.003 |
| Child-Pugh score | 5.51 ± 0.85 | 5.91 ± 1.32 | 0.344 |
| Duration of anti-viral Tx. (mo) | 20 (0-72) | 6 (1-276) | 0.001 |
| Mean tumor surveillance period (mo) | 6.35 ± 1.69 | 8.71 ± 2.86 | < 0.001 |
| Total follow-up duration (d) | 842.51 ± 702.57 | 801.74 ± 713.24 | 0.721 |
UICC: Union Internationale Contre le Cancer; CLIP: Cancer of the Liver Italian Program; LN: Lymph node; ALT: Alanine aminotransferase; AFP: Alpha-fetoprotein; AST: Aspartate aminotransferase; HBV: Hepatitis B virus; CRP: C-reactive protein.